Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
2.690
+0.080 (3.07%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Sight Sciences Revenue
In the year 2024, Sight Sciences had annual revenue of $79.87M, down -1.47%. Sight Sciences had revenue of $19.07M in the quarter ending December 31, 2024, with 1.72% growth.
Revenue (ttm)
$79.87M
Revenue Growth
-1.47%
P/S Ratio
1.67
Revenue / Employee
$369,750
Employees
216
Market Cap
136.54M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SGHT News
- 25 days ago - Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th - GlobeNewsWire
- 6 weeks ago - Sight Sciences, Inc. (SGHT) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 6 weeks ago - Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance - GlobeNewsWire
- 7 weeks ago - Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting - GlobeNewsWire
- 2 months ago - Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025 - GlobeNewsWire
- 2 months ago - Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day - GlobeNewsWire
- 4 months ago - Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options - GlobeNewsWire
- 5 months ago - Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire